• Engineered LRRK2 kinase-domain inhibitor scaffold 39m ago
  • Huntingtin polyQ-tract recognizer 39m ago
  • TDP-43 N-terminal stabilizer 39m ago
  • α-Synuclein aggregation inhibitor 39m ago
  • Anti-Aβ42 binder de novo 39m ago

refund-happy

test open
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
—
Novelty
—
Mechanistic
—
Druggability
—
Priority
—
Importance
—
Tractability
—
Market price
50%

Description

x